Regulatory affairs expert: what they really do and how to hire one

Most searches for "Regulatory affairs expert" surface career guides aimed at people entering the field. This article is written for the other side of that equation: the regulatory lead, COO, or program manager who needs to hire or engage one. It gives a defensible framework for deciding when, how, and at what scope. Use it before a submission deadline or escalating risk forces the decision.

This guide covers how an expert differs from a specialist or manager, when to bring one in by development stage, how to vet candidates rigorously, how to structure a statement of work (SOW) with acceptance criteria, which KPIs to track, and what tools a capable expert should be fluent in. It draws on frameworks from RAPS, FDA, EMA, and ICH guidance where they materially strengthen the guidance.

Overview

If you face submission deadlines or decisions that materially change evidentiary burden, engage a regulatory affairs expert early. As RAPS describes, regulatory professionals ensure compliance with health authority requirements to support safe and effective product development — but that label spans a wide spectrum of seniority, sector knowledge, and decision authority.

A specialist executing tasks under direction and an expert setting submission strategy and owning regulator interactions are fundamentally different hires. That distinction matters when stakes are high: borderline classification decisions, a first IND or BLA filing, an EU MDR technical documentation build, or a multi-region launch with diverging evidence expectations. The wrong engagement model or delayed engagement commonly yields clock-stops, deficiency letters, and significant rework costs instead of a clean submission.

This guide moves from definition to decision: what "expert" means across sectors and pathways, when to involve one, how to vet candidates, how to structure an SOW, which KPIs to track, and the tool stack an expert should use.

Defining a regulatory affairs expert (vs specialist, manager, consultant)

The label "expert" is not a formal job title in regulatory affairs. Organizations use specialist, manager, director, consultant, and advisor labels differently, and that ambiguity creates real hiring risk.

What distinguishes an expert is decision authority, scope ownership, and demonstrated outcomes rather than the business card. A specialist typically executes defined tasks — compiling a section, formatting a submission sequence, tracking change logs — within a framework set by someone more senior. A manager coordinates cross-functional activity and may own a submission program end to end. A regulatory affairs consultant, as described by practices like Parexel's regulatory consulting group, often serves as the primary regulatory contact for clients and develops comprehensive regulatory strategies for product development and market entry.

An expert, as used in this article, independently sets strategy, anticipates regulator expectations before meetings, and makes defensible trade-off calls when evidence gaps or classification questions arise. The practical test: can this person represent the regulatory position in an FDA meeting or a notified body interaction without supervision? Can they identify decisions at a given development stage that will create submission risk two years downstream? Those are expert-level functions.

RAPS organizes competencies around strategy, submissions management, and regulatory intelligence — an expert operates across all three domains rather than within just one.

Sector-specific expertise: drugs, biologics, devices, diagnostics/IVD, SaMD/AI, cosmetics, nutritionals

"Expert" carries different requirements by sector and risk class because pathways, evidence standards, and regulator interactions differ enough that experience in one area often does not transfer cleanly to another.

For drugs and biologics, experts understand IND, NDA/BLA, ANDA pathways, CTD/eCTD structure under ICH M4, clinical hold risk, and biosimilar pathways under 21 CFR Part 600. Biologic filings require knowledge of CBER guidance and comparability protocols for manufacturing changes.

For medical devices and IVDs, US pathways include 510(k), De Novo, and PMA. EU practice now requires EU MDR (Regulation 2017/745) and EU IVDR (Regulation 2017/746) expertise for CE marking, including technical documentation, clinical evaluation reports, and notified body interactions. The UKCA framework has diverged post-Brexit and requires its own knowledge. For SaMD and AI/ML products, the landscape is evolving; FDA's Digital Health Center of Excellence and frameworks for change control add complexity a generalist may not manage.

Combination products that mix hardware, software, and diagnostics pose additional jurisdictional and classification challenges. Cosmetics, nutritionals, and consumer products follow different frameworks entirely — FDA DSHEA for dietary supplements, MoCRA for cosmetics, and FTC advertising rules. Pharma or device expertise does not substitute.

The practical hiring implication: always specify sector, pathway, and target markets before evaluating candidates.

Decision authority and deliverables by pathway

Mapping expert authority to concrete deliverables avoids scope creep and misaligned expectations.

For 510(k) and De Novo submissions, an expert owns the regulatory strategy determination — substantial equivalence rationale or De Novo classification analysis. They select predicates, prepare the substantial equivalence summary or De Novo request, develop the response strategy for Additional Information requests, and oversee performance testing plans and labeling claims.

For IND/NDA/BLA programs, deliverables typically include the regulatory strategy memorandum, pre-IND meeting request and briefing package, IND narrative sections, NDA/BLA submission strategy, and labeling negotiation positions. Experts also lead response planning for Complete Response Letters and major deficiencies.

For EU MDR/IVDR submissions, experts own or supervise the clinical evaluation plan and report strategy, PMCF plans, technical documentation architecture, and notified body interaction strategy. They must navigate applicable common specifications and harmonized standards.

These artifacts become acceptance-criteria anchors for a well-structured SOW — a point developed in detail in the SOW section below.

When to bring in an expert (by development stage and risk)

Engaging regulatory expertise only as a submission approaches is often the wrong timing. An expert's highest-value contributions usually occur earlier, when technology, clinical design, and manufacturing decisions are still reversible.

Regulatory strategy determines what evidence you need, which development choices are defensible, and which create submission risk. Engaging an expert after those decisions are locked — after a clinical protocol is finalized or manufacturing processes are set — limits them to defensive damage control. They can reduce harm but rarely eliminate it. RAPS frames regulatory expertise as strategic rather than administrative for this reason.

For drug and biologic programs, meaningful regulatory input should begin before an IND is filed — ideally during candidate selection and proof-of-concept, when dosing, route, and population choices remain open. For devices, involve an expert at design inputs when intended use, indications, and performance specifications are defined. These elements directly determine pathway and clinical evidence burden.

Escalation triggers and red flags

Certain situations should trigger immediate expert engagement regardless of stage because they substantially increase the risk of deficiency, delay, or pathway reset:

• Borderline classification or dual-pathway uncertainty, including device vs drug vs combination product and software components invoking digital health rules.
• Novel technology or first-in-class submissions without clear predicate or established evidence standards.
• Multi-region or parallel submission strategies with divergent dossier requirements.
• Complex labeling or promotional claims requiring coordination with FDA OPDP or equivalents.
• Post-market surveillance or PMCF gaps not scoped from the design phase.
• Inspection findings or 483 observations tied to regulatory documentation, design control, or labeling.
• Large-scale change management — manufacturing process changes, site transfers, post-approval supplements — that may need prior approval.

Each is a decision node where incorrect assumptions can cascade and take months or years to correct.

Risks of delaying regulatory input

The most visible cost of late involvement is deficiency or Additional Information letters that place submissions on administrative hold. Clock-stops vary by submission type and can extend for months.

Less visible is divergent evidence design. Clinical data collected without regulatory input may not meet the regulator's evidentiary standard, forcing expensive rebuilds. For EU MDR, an inadequate clinical evaluation report can lead to notified body rejection of technical documentation outright.

Labeling rework is a third common failure mode. When marketing-created labeling exceeds validated indications or asserts comparative claims, revisions pull in QA, regulatory, medical, and legal — and may require regulatory notification or approval. An expert engaged at labeling strategy prevents most such issues.

In-house hire vs external consultant/fractional

Choosing between in-house capability and external consultants is rarely binary. Most organizations operate a hybrid, and the practical question is where to set boundaries given team maturity, submission load, and geographic footprint.

An in-house expert builds institutional memory: familiarity with manufacturing platforms, CMC history, agency correspondence, and quality systems. That context is expensive to transfer repeatedly to consultants. Organizations with stable, high-volume submission pipelines — especially commercial pharma managing ongoing supplements and post-approval commitments — often justify in-house depth.

A regulatory affairs consultant brings breadth, speed, and flexibility. Consultants draw on experience across multiple programs, current regulator behavior, and evolving guidance. An in-house team focused on a single platform may lack that breadth. For early-stage companies, startups, or organizations entering a new market or pathway, a consultant or fractional expert is frequently faster and more capital-efficient.

A practical hybrid: an in-house regulatory manager or director owns strategy and continuity, supported by a consultant providing depth for specific pathways, regions, or high-risk junctures such as a first NDA, a PMA clinical strategy, or a notified body transition under EU MDR.

Decision matrix: team maturity, region count, risk class, budget, and timeline

Score your situation across the five dimensions below. If three or more factors align with consultant conditions, an external engagement is likely preferable. Three or more in-house factors favors hiring. Hybrid conditions call for scoped consultant support alongside an in-house lead.

Team maturity

In-house: existing regulatory team with submission experience; gap is capacity.

Consultant: no in-house regulatory staff; first submission in this pathway or region.

Region count

In-house: single-market focus with established agency relationships.

Consultant: multi-region launch requiring local in-country expertise.

Product risk class and pathway

In-house: well-understood pathway with precedent submissions.

Consultant: novel or high-risk products — Class III PMA, first-in-class BLA, SaMD with AI/ML.

Budget and timeline

In-house: sustained multi-year program justifying a full-time hire.

Consultant: short-term engagement (6–18 months) with defined deliverables.

Institutional memory need

In-house: deep CMC history, ongoing post-market obligations requiring continuity.

Consultant: discrete program with manageable knowledge transfer at close.

Engagement models and typical scopes

Three structures cover most situations. A retainer model provides responsive availability over months for strategy calls, agency preparation, and reactive support; it suits pre-submission planning and post-approval commitments with unpredictable questions. A per-deliverable model ties payment to specific outputs such as a strategy memo, pre-submission package, or 510(k) summary; it creates clear accountability but requires anticipating deliverables upfront. A milestone-based SOW is the most structured option for defined submission programs, with milestones tied to development and submission gates and verifiable acceptance criteria.

Whichever model you choose, map handoffs explicitly in the SOW: QA/QMS for design control, CMC for Module 3 content, clinical/medical for study design and labeling, publishing for eCTD sequencing. Clarify version control and review workflows to prevent the rework and version drift that consistently slow submission programs.

How to vet a regulatory affairs expert

Vetting requires more than a CV and an RAC certificate. Surface pathway- and region-specific track record, the quality of agency interactions managed, and tool proficiency. Structural submission errors and missing metadata cause avoidable defects regardless of strategic quality.

Source candidates from RAPS consultant directories, specialized life-sciences staffing firms, or CROs with regulatory practices. In initial screening, ask for a list of submissions the candidate managed to completion, including pathway, region, whether deficiencies occurred, and how they were resolved. Experienced experts discuss submissions at that level of detail; vague or generalized claims are a meaningful red flag.

Track record signals and reference checks

Verify these items when assessing track record:

• Pathway-specific submission history: completed 510(k), De Novo, PMA, IND, NDA, BLA, or EU MDR/IVDR submissions with years, product types, and outcomes.
• Deficiency or AI letter history: not automatically disqualifying, but candidates should explain root causes and resolutions clearly; repeated similar deficiencies are a warning sign.
• Agency interaction experience: pre-submission meetings (Q-submissions, pre-IND), Type A/B/C meetings, and notified body interactions with documented outcomes.
• Inspection support: involvement in FDA inspections, MHRA audits, or notified body audits and any 483 response work.
• References: ask prior clients or employers about strategic advice quality, how the candidate handled unexpected agency responses, and whether they would re-engage.

RAC certification — RAC-US, RAC-EU, or RAC-Drugs — demonstrates baseline tested knowledge. Treat it as a minimum screen, not a substitute for pathway-specific track record.

Interview prompts that surface real capability

Use scenario-based prompts to force structured reasoning rather than rehearsed answers:

• Walk through building a regulatory strategy for a Class IIb device targeting FDA clearance and EU MDR CE marking simultaneously. Where do evidence packages diverge and how do you sequence the work?
• You receive an FDA Additional Information request on day 75 of a 510(k). What is your immediate response process and the most common root causes you investigate?
• A team proposes labeling beyond the validated indication. What process do you use to evaluate and document the decision?
• How do you manage a situation where clinical data does not fully support the intended pathway and the timeline is already committed?
• Describe your experience with notified body technical documentation review under EU MDR and common gaps you find in clinical evaluation reports.

Strong candidates provide specific, structured answers, name agencies, describe trade-offs, and acknowledge limits. Generalities or inability to describe past difficult situations suggest the candidate may not perform at expert level under submission pressure.

Tools familiarity and working style

A capable regulatory expert operates within a defined toolchain, and fluency affects submission quality and speed. For eCTD/CTD, the expert should understand ICH M4 structure, lifecycle operations (replace, delete, append) on sequence management, and common structural or metadata issues that generate Refuse to File or technical rejections. Ask them to describe their validation steps — experts with repeatable processes will describe them specifically.

For regulatory intelligence, ask how the candidate tracks guidance changes from FDA, EMA, ICH, MHRA, and Health Canada and translates them into submission decisions. Structured processes with documented impact assessment — rather than ad hoc monitoring — are a meaningful differentiator, particularly for consultants managing multiple clients or programs simultaneously.

Statement of work essentials for RA engagements

A vague SOW creates disputes about quality and scope creep. An overly prescriptive SOW constrains expert judgment. The goal is a document that defines what is delivered, when, and how acceptance is determined without scripting strategy.

The SOW preamble should define submission pathway and target region, product type and risk class, program timeline, and key dependencies — specifically what the expert needs from you and by when. That scoping prevents common failures where an expert cannot deliver because internal inputs such as manufacturing data, clinical results, or design documentation were not provided on schedule.

Every SOW should include a change control clause. Regulatory programs evolve: development results shift evidence packages, agency meetings produce new guidance, and manufacturing changes require strategy revisions. A documented change control process prevents informal scope expansion and keeps the engagement predictable.

Deliverable checklist by pathway

Use this checklist as a starting point and adapt to your scope.

510(k) / De Novo

• Regulatory pathway determination memo (substantial equivalence or De Novo rationale)
• Pre-submission (Q-submission) request and meeting package
• Draft 510(k) summary or De Novo request with predicate analysis, performance testing strategy, and labeling review
• Response to FDA Additional Information request, if issued
• Final cleared device labeling review

IND / NDA / BLA

• Regulatory strategy memorandum
• Pre-IND meeting request and briefing document
• IND narrative sections (pharmacology, toxicology, clinical study introductions)
• NDA/BLA submission strategy and labeling negotiation plan
• Integrated Summary of Safety (ISS) and Efficacy (ISE) strategy review
• Response to Complete Response Letter or major deficiency

EU MDR / IVDR

• Regulatory strategy and classification justification memo
• Technical documentation architecture review
• Clinical evaluation plan (CEP) and clinical evaluation report (CER) strategy review
• Post-market surveillance (PMS) and PMCF plan review
• Notified body interaction plan and Q&A preparation
• Declaration of Conformity review

These deliverables map to FDA guidance, EMA procedural guidance, and ICH guidelines you can use to verify content standards against published regulator expectations.

Milestones, acceptance criteria, and readiness checks

Milestones should align with program gates, not arbitrary dates. For a 510(k) program, sensible gates include: regulatory pathway confirmed (with memo), pre-submission meeting held, draft submission package complete, submission filed, and AI response submitted if applicable. Each milestone needs an acceptance criterion defining what "complete" means — not just a date.

For submission packages, structural readiness is a verifiable acceptance criterion. An eCTD sequence that passes structural and metadata checks against ICH eCTD specifications and the FDA Technical Conformance Guide is more acceptable than one submitted without validation. Browser-based eCTD validators that run CFR, ICH, and FDA TRC structural checks across Modules 1–5 — such as Assyro's free eCTD validator, which validates lifecycle XML, checksum manifests, hyperlinks, and metadata locally without uploading files to a server — provide a quick readiness gate before accepting deliverables.

Specify reporting cadence: weekly status updates or bi-weekly calls during drafting, and immediate notification for unexpected agency communication or guidance changes that materially affect strategy.

Sample SOW field layout (copy-paste)

Populate each field before legal or procurement review:

• Engagement title: [Regulatory pathway] [Product name] — Regulatory Affairs Expert Services
• Scope summary: submission pathway, target region(s), product type, and risk class in two to three sentences
• In-scope deliverables: specific deliverables by name; reference regulator guidance where applicable
• Out-of-scope exclusions: functions not covered (e.g., clinical trial management, CMC writing, eCTD publishing, QMS documentation)
• Timeline and milestones: each milestone with target date and acceptance criterion
• Dependencies: what the client commits to provide and by when (design docs, clinical data, CMC package, prior agency correspondence)
• Roles and responsibilities: expert's decision authority; client-side counterpart and escalation path
• Change control: process for requesting and approving scope changes and handling out-of-scope requests
• Reporting cadence: frequency and format of status updates; escalation triggers
• Acceptance criteria: per-deliverable criteria (structural validation, completeness against guidance, client review sign-off)
• Confidentiality and IP: handling of prior agency correspondence and regulatory strategy documents
• Termination and handoff: early termination conditions; document repository and open issues log
• Compensation structure: milestone-based, retainer, or per-deliverable; specify payment trigger (milestone accepted)

KPIs and ROI: measuring expert impact

Define KPIs before engagement to avoid accountability gaps. Metrics fall into two phases: submission quality and review efficiency during the program, and post-market and labeling performance ongoing. The business logic is straightforward — regulatory delays are expensive, and an expert who reduces clock-stop probability or deficiency letters delivers measurable value even when that value is framed as avoided cost.

For financial modeling, use a program-specific cost-of-delay approach rather than general benchmarks. Tools that let you configure your program baseline and model submission-cycle time savings and avoided rework costs against engagement fees — such as Assyro's regulatory ROI calculator, which generates an annualized financial impact estimate you can share with finance — can help present the engagement cost versus program exposure in terms a CFO will engage with.

Submission-quality and review-efficiency metrics

Track these program-level metrics and compare across submissions when possible:

• Deficiency or AI rate: number of deficiencies, AI letters, or Additional Information requests per submission.
• Number of internal review cycles before submission: more than two to three cycles on a well-scoped program suggests process or scope gaps.
• Clock-stops and duration: combined duration of clock-stops is a direct measure of submission and response quality.
• Pre-submission acceptance rate: whether FDA Q-submission or EMA scientific advice positions were accepted or required major revision.
• Time from submission to clearance or approval: benchmark against PDUFA/MDUFA or pathway typical timelines.
• RTF or Refuse to Accept rate: structural or completeness issues that prevent review from starting.

Post-market and labeling cycle metrics

Include post-market metrics that reflect ongoing regulatory performance:

• Labeling change lead time: time from change request to approved labeling revision.
• Vigilance and complaint timeliness: proportion of serious incident reports submitted within required timeframes.
• CAPA closure rate with regulatory linkage: proportion of CAPAs closed on time with adequate root-cause analysis.
• PMS plan compliance: whether PMS activities and PSUR/PMCF reporting occur on schedule.

Cost-of-delay considerations

Quantify cost of delay using your revenue projections and development-cost structure. For commercial products, each delayed week has calculable revenue impact. For PDUFA action dates, a 90-plus day clock-stop materially shifts commercial and investor timelines. Modeling these impacts against expert engagement costs — rather than treating the engagement as a line-item expense — is the clearest way to present a structured case to finance or a board.

Regional strategy beyond the U.S.

FDA fluency is baseline for many US-focused experts, but parallel filings and multi-region strategies introduce divergences that require additional depth. ICH harmonization helps through M4 CTD and Q1–Q14, but classification rules, evidence expectations, labeling, and procedural timelines often diverge in ways that affect strategy from the earliest development stages.

The expert appropriate for a US-only 510(k) program may not be the right leader for simultaneous FDA/EMA/MHRA filings. Assuming otherwise is a common and costly mistake that tends to surface late in the dossier build when it is most expensive to correct.

When to involve local experts

Engage in-country or region-specific expertise alongside your lead expert when:

• Local language and labeling are mandatory (China NMPA, Japan PMDA, Health Canada bilingual requirements).
• National procedural differences matter — post-Brexit MHRA routes differ from EU procedures in meaningful ways.
• Device classification differs across jurisdictions (FDA vs EU MDR rules for the same product).
• Local clinical evidence expectations require domestic or bridging studies (PMDA, NMPA).
• Authorized Representative or Responsible Person requirements apply under EU MDR or MHRA.

These are legal and procedural necessities, not optional supports.

Common divergences affecting evidence and labeling

Evidence package expectations diverge more than many teams anticipate. FDA's benefit-risk framework is outcome-focused and flexible on study design, while EMA may favor more prescriptive endpoints and comparators in certain therapeutic areas. Clinical evaluation under EU MDR is continuous and lifetime-focused; FDA's 510(k) substantial equivalence analysis is point-in-time. These structural differences mean an evidence strategy designed purely for one agency will often require material rework for the other.

Labeling divergences are disruptive when discovered late. NMPA requires Chinese-language labeling and specific registration formats; PMDA has unique translation conventions; Health Canada mandates English and French labeling. Each requires target-market expert review to avoid launch delays caused by late-stage labeling rework.

Tools and systems experts actually use

A capable expert is both strategist and practitioner within a technical toolchain. Evaluate tool proficiency because submission quality and efficiency depend on navigating systems that produce, validate, and manage regulatory content. The toolchain spans eCTD/CTD structure and validation, regulatory information management (RIM) and IDMP for data governance, and regulatory intelligence for change monitoring.

eCTD/CTD structure and validation basics

The eCTD format is required for NDA, BLA, IND, and many centralized EMA submissions. Structure stems from ICH M4 with implementation details in FDA's Technical Conformance Guide and EMA technical guidance. Structural and metadata validation should be an ongoing drafting process to prevent late-cycle defects — not a final-step check before publishing.

Common eCTD problems include broken hyperlinks, incorrect lifecycle operations, checksum mismatches, and TOC metadata errors, all of which are avoidable with iterative validation during content development. Workspaces where authors, RA, RegOps, QA, CMC, and publishing teams review the same controlled sequence with shared owners, comments, and traceability reduce last-minute publishing errors. For deliverable acceptance gates, a quick browser-based structural scan — such as the Assyro eCTD validator, which runs 358 CFR, ICH, and FDA TRC checks across Modules 1–5 and validates lifecycle XML, hyperlinks, and checksum manifests locally — gives hiring teams a fast, document-safe readiness check before accepting submission deliverables.

RIM, IDMP, and regulatory intelligence in practice

RIM systems are the data backbone for tracking product registrations, submission histories, agency correspondence, and lifecycle events across markets. For multi-region portfolios, RIM is essential to avoid missed deadlines and registration gaps. IDMP (ISO 11238, 11239, 11240, 11615, 11616) supports EMA SPOR data requirements; organizations not IDMP-ready will face remediation costs as SPOR requirements tighten.

Regulatory intelligence — monitoring guidance changes, draft regulations, and procedural updates across FDA, EMA, ICH, MHRA, and Health Canada — is most reliably handled with structured tools that provide change alerts, impact-assessment workflows, and audit-ready documentation of evaluations and actions. Platforms that track ICH Q1 through Q14 automatically and embed change alerts directly into submission validation workflows, rather than treating intelligence as a separate research function, offer a meaningful operational advantage. Verify that a candidate's regulatory intelligence practice matches this level of structure.

On-page utility: hiring checklist and SOW template

The following assets are ready to copy into vetting or procurement workflows.

10-point vetting checklist

Use and verify each item in candidate evaluation:

1. Pathway-specific submission history: confirm completed submissions in your target pathway with product type and outcome.

2. Region-specific experience: verify direct experience with each target jurisdiction (FDA, EMA, MHRA, Health Canada, PMDA, TGA, NMPA).

3. Deficiency and AI letter history: candidate can describe a deficiency, its root cause, and the resolution.

4. Agency interaction record: pre-submission meetings, Type A/B/C requests, and notified body interactions with documented outcomes.

5. Inspection support experience: involvement in FDA inspections or notified body audits and related 483 or audit response support.

6. RAC certification or equivalent: verify current status and specialty; treat as a minimum screen.

7. eCTD tool proficiency: candidate can describe structural validation processes and common lifecycle operation errors.

8. Regulatory intelligence practice: documented process for monitoring guidance changes and translating them into submission decisions.

9. Reference verification: at least two references who can speak to strategic quality and handling of unexpected agency responses.

10. Conflict-of-interest stance: approach to client preferences that conflict with regulatory defensibility and policy on declining work outside their expertise.

Copy-paste SOW fields

• Engagement title: [Pathway] [Product] — Regulatory Affairs Expert Services
• Scope summary: Pathway, region(s), product type, risk class, and objective (one paragraph)
• In-scope deliverables: Named list with regulator guidance reference for each
• Out-of-scope: Named exclusions (CMC writing, clinical trial management, eCTD publishing, QMS documentation)
• Milestones: Name, target date, acceptance criterion for each milestone
• Dependencies: Client-provided inputs with committed delivery dates
• Roles: Expert decision authority; client counterpart and escalation path
• Change control: Process for requesting, evaluating, and approving scope changes
• Reporting cadence: Frequency, format, and escalation triggers
• Acceptance criteria: Per-deliverable criteria (structural validation, completeness check, client sign-off)
• Confidentiality and IP: Document handling and regulatory strategy ownership
• Termination and handoff: Conditions; repository and open issues log requirements
• Compensation: Structure (milestone / retainer / per-deliverable); payment trigger

Quick timeline snapshot by pathway

These are typical FDA review goal ranges grounded in public MDUFA and PDUFA targets. They reflect regulator clock time, not total program duration including preparation.

• 510(k): FDA review goal is 90 days from acceptance; total time varies with AI requests.
• De Novo: FDA has a 150-day review goal for most requests; complex devices may take longer.
• PMA: FDA review goal is 180 days; advisory committees and clinical holds can extend timelines.
• IND: FDA has 30 days to respond to an initial IND; clinical hold risk is the primary variable.
• NDA / BLA (standard): FDA review goal under PDUFA is 12 months from filing; priority review is 6 months.
• EU MDR (CE marking): No fixed regulatory clock; notified body timelines vary, often 12–24+ months for high-risk devices.
• MHRA (UK): Post-Brexit national routes have published targets; the standard national procedure target is 210 days with variations.

These anchors are starting points. Actual timelines depend on submission quality, agency workload, and deficiency rounds — all areas where a well-engaged regulatory affairs expert makes a measurable difference.

---

Ready to act on this framework? Before your next engagement or headcount request, run through the five-factor decision matrix in the hire vs consultant section to identify your model, then use the SOW field layout to scope deliverables before legal review. If pre-submission eCTD readiness is part of the acceptance criteria you are setting, Assyro's free eCTD validator and regulatory ROI calculator are browser-based utilities you can use today — no file uploads, no account required — to establish a baseline before your expert engagement begins.